Kyntra Bio, Inc. in brief
Kyntra Bio, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its last known market value was $79 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $6 M and a net profit of $183 M. It employs about 566 people and Thane Wettig is its chief executive. Its largest product and service lines by sales in 2025 were Drug Product Revenue, Net (91%) and Development and Other Revenue (9%). By market, the largest shares of its 2025 sales came from Europe (88%) and Japan (12%). Its shares trade under the symbol KYNB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Kyntra Bio, Inc.
FibroGen is a Biotechnology company. It collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa. The headquarters is in USA.
Kyntra Bio, Inc. timeline
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- 2019
- 💰Record revenue of $257 millionFY2019, the highest of the 8 years on record.
- 2026
- ✎Renamed Kyntra Bio, Inc.Formerly Fibrogen Inc.
Events of Kyntra Bio, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,077 (Jan 2020) · #1,278 (Jan 2021) · #2,361 (Jan 2022) · #1,708 (Dec 2022) · #3,664 (Jul 2023) · #3,851 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 2848.6%
- Operating margin
- -712.7%
- Return on equity
- —
- Liabilities / assets
- 96.3%
- Revenue growth
- -78.3%
- R&D / revenue
- 365.2%
- Revenue per employee
- $11 K
- Profit per employee
- $324 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $6M | -78.3% | $-46M | $183M | 2848.6% |
| Dec 2024 | $30M | -36.7% | $-150M | $-48M | -160.6% |
| Dec 2023 | $47M | -66.7% | $-323M | $-284M | -607.3% |
| Dec 2022 | $141M | -40.2% | $-301M | $-294M | -208.7% |
| Dec 2021 | $235M | +33.5% | $-289M | $-290M | -123.3% |
| Dec 2020 | $176M | -31.3% | $-192M | $-189M | -107.4% |
| Dec 2019 | $257M | +20.5% | $-89M | $-77M | -30.0% |
| Dec 2018 | $213M | — | $-87M | $-86M | -40.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-5M | $45.37 | — |
| Dec 2024 | $-138M | $0M | $-138M | $-11.89 | — |
| Dec 2023 | $-315M | $3M | $-318M | $-2.92 | — |
| Dec 2022 | $-146M | $4M | $-150M | $-3.14 | — |
| Dec 2021 | $-82M | $5M | $-87M | $-3.14 | — |
| Dec 2020 | $82M | $4M | $78M | $-2.11 | — |
| Dec 2019 | $-79M | $6M | $-84M | $-0.89 | — |
| Dec 2018 | $-76M | $8M | $-84M | $-1.03 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 6, 20268-KCurrent reportListing notice
- Oct 1, 20268-KCurrent reportDirectors or officers changed
- Aug 31, 20268-KCurrent reportMaterial agreement · New financial obligation · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 16, 20268-KCurrent reportShareholder vote
- Jun 9, 20268-KCurrent reportOther events
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
- Apr 27, 2026DEF 14AProxy statement
- Apr 9, 20268-KCurrent reportListing notice
- Mar 16, 202610-KAnnual report · period to Dec 2025
Official filings of Kyntra Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $6 M
- Operating income
- $-46 M
- Net income
- $183 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $120 M
- Total liabilities
- $115 M
- Total equity
- $-30 M
As of December-2025
Top 35 institutional investors in Kyntra Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 400,000 | 0 (0.00%) | 9.88% | $3 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 159,950 | 0 (0.00%) | 3.95% | $1 M | Nov 13, 2026 |
| 3 | Acadian Asset Management LLC | 105,585 | 0 (0.00%) | 2.61% | $1 M | Nov 9, 2026 |
| 4 | BlackRock, Inc. | 84,330 | 0 (0.00%) | 2.08% | $1 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 41,387 | -1,832 (-4.24%) | 1.02% | $0 M | Nov 6, 2026 |
| 6 | HighTower Advisors, LLC | 39,746 | 0 (0.00%) | 0.98% | $0 M | Nov 10, 2026 |
| 7 | Renaissance Technologies LLC | 35,281 | +8,200 (+30.28%) | 0.87% | $0 M | Nov 12, 2026 |
| 8 | Two Sigma Investments, LP | 31,317 | -8,194 (-20.74%) | 0.77% | $0 M | Nov 16, 2026 |
| 9 | Citadel Advisors LLC | 24,144 | New | 0.60% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 24,105 | 0 (0.00%) | 0.60% | $0 M | Nov 13, 2026 |
| 11 | Oppenheimer & Co Inc | 23,672 | New | 0.58% | $0 M | Oct 26, 2026 |
| 12 | Birchview Capital, LP | 22,566 | 0 (0.00%) | 0.56% | $0 M | Nov 13, 2026 |
| 13 | State Street Corp | 20,284 | 0 (0.00%) | 0.50% | $0 M | Nov 12, 2026 |
| 14 | Gsa Capital Partners LLP | 20,161 | +4,464 (+28.44%) | 0.50% | $0 M | Nov 16, 2026 |
| 15 | ADAR1 Capital Management, LLC | 14,341 | New | 0.35% | $0 M | Nov 16, 2026 |
| 16 | UBS Group AG | 8,768 | +911 (+11.59%) | 0.22% | $0 M | Nov 10, 2026 |
| 17 | Royal Bank Of Canada | 2,132 | +1,994 (+1444.93%) | 0.05% | $0 M | Nov 16, 2026 |
| 18 | Vanguard Global Advisers, LLC | 1,424 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 19 | Group One Trading LLC | 1,116 | -3,290 (-74.67%) | 0.03% | $0 M | Nov 10, 2026 |
| 20 | Axiom Investment Management LLC | 704 | 0 (0.00%) | 0.02% | $0 M | Nov 3, 2026 |
| 21 | Tower Research Capital LLC (TRC) | 567 | -546 (-49.06%) | 0.01% | $0 M | Nov 16, 2026 |
| 22 | Morgan Stanley | 487 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 23 | Harbour Investments, Inc. | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 24 | National Bank Of Canada /fi/ | 193 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 25 | Nova Financial LLC | 160 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
Show all 35: investors 26 to 35
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Osaic Holdings, Inc. | 102 | -80 (-43.96%) | 0.00% | $0 M | Nov 12, 2026 |
| 27 | BNP Paribas Financial Markets | 46 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | SBI Securities Co., Ltd. | 16 | -136 (-89.47%) | 0.00% | $0 M | Oct 22, 2026 |
| 29 | Jpmorgan Chase & Co | 12 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 30 | FMR LLC | 8 | New | 0.00% | $0 M | Nov 10, 2026 |
| 31 | Cassaday & Co Wealth Management LLC | 4 | New | 0.00% | $0 M | Oct 27, 2026 |
| 32 | Barclays PLC | 3 | New | 0.00% | $0 M | Nov 6, 2026 |
| 33 | CFG Wealth Management Services, Inc. | 3 | New | 0.00% | $0 M | Oct 21, 2026 |
| 34 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 35 | Smithfield Trust Co | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Kyntra Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 114,179 | $1 M | 2.8% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 42,265 | $0 M | 1.0% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 21,079 | $0 M | 0.52% | <0.01% | −0.6% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,005 | $0 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 5,744 | $0 M | 0.14% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 3,506 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Capital Opportunity FundPRIMECAP Management Company | 2,716 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 1,991 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 185 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 22 | $0 M | <0.01% | <0.01% | +4.8% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Kyntra Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thane WettigCEO, Director | Grant or award | +2,500 | $2.924 | $7 K | 29,296 | Form 4 |
| filed | David DeLuciaChief Financial Officer | Shares withheld for tax | -22 | $8.550 | $188 | 4,355 | Form 4 |
| filed | Thane WettigCEO, Director | Shares withheld for tax | -209 | $8.550 | $2 K | 26,796 | Form 4 |
| filed | Thane WettigCEO, Director | Shares withheld for tax | -198 | $6.710 | $1 K | 27,005 | Form 4 |
| filed | David DeLuciaChief Financial Officer | Shares withheld for tax | -52 | $6.710 | $349 | 4,377 | Form 4 |
| filed | Thane WettigCEO, Director | Buyamended | +2,800 | $7.090 | $20 K | 27,203 | Form 4/A |
| filed | Thane WettigCEO, Director | Buy | -2,800 | $7.090 | $20 K | 27,203 | Form 4 |
| filed | David DeLuciaChief Financial Officer | Shares withheld for tax | -60 | $6.840 | $410 | 4,429 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Kyntra Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-09-10 17:23 UTC, code LUDP, resumed 17:28 UTC
- 2025-06-16 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 228 shares at $8.55
- : 164 shares at $8.00
- : 458 shares at $8.10
- : 151 shares at $7.98
- : 800 shares at $7.52
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Kyntra Bio, Inc. scorecard#
Passes 5 of the 14 checks that could be worked out: strongest in growth (2 of 6), weakest in profitability (1 of 4). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth2 of 6
- ✗Revenue grew in the newest year-78.3%Revenue down 78.3% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-64.2%-64.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-64.2%-64.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year45.37 vs -11.89Diluted EPS 45.37 in fiscal 2025 against -11.89 the year before (report's currency).
- ✓Net income higher than five years earlier$183 M$183 M in fiscal 2025 against -$189 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability1 of 4
- ✓Profitable in the newest year$183 MNet income $183 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-712.7%-712.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-712.7%-712.7% in fiscal 2025 against -213.9% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.4×Current ratio 3.39 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.2×Operating income -5.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.0%Diluted shares up 1.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Kyntra Bio, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -712.7% | -60.5% | |
| Revenue growth, 3 years a year | -64.2% | 12.9% | |
| Revenue growth | -78.3% | 15.8% | |
| Free cash flow margin | -74.7% | -61.5% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 78.3% against the year before.
- Free cash flow was negative: -$5 million.
- Only -3% of net income arrived as cash from operations.
- Shareholders' equity is negative: -$30 million.
Kyntra Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 6.4−78.3%100% | 30−36.7%100% | 47r148−66.7%100% | 141−40.2%100% | 235+33.5%100% | 176−31.3%100% | 257+20.5%100% | 213+62.6%100% | 131r126−28.5%100% | 183r180—100% | |
| Cost of revenue | 0.6−96.4%8.6% | 16+293%52.5% | 4.0r19−80.5%8.5% | 20+57.6%14.4% | 13+45.1%5.5% | 8.9+673%5.0% | 1.1—0.4% | — | — | — | |
| Research and development | 24−75.4%365% | 96−64.1%323% | 266r283−10.2%569% | 297−23.3%211% | 387+53.0%164% | 253+20.9%143% | 209−11.3%81.6% | 236+20.0%111% | 197+5.0%150% | 187—102% | |
| Selling, general and administrative | 28−43.8%430% | 49−43.0%167% | 86r115−30.6%185% | 125+0.6%88.6% | 124+16.5%52.7% | 106−21.5%60.3% | 135+112%52.8% | 64+23.3%30.0% | 52—39.5% | — | |
| General and administrative | — | — | — | — | — | — | — | 64+23.3%30.0% | 52+12.5%39.5% | 46—25.1% | |
| Operating expenses | — | — | — | — | — | 368+6.4%209% | 346+15.4%135% | 300+20.7%141% | 248+6.5%190% | 233—127% | |
| Total costs and expenses | 52−70.9%813% | 180−51.3%608% | 370r430−16.4%790% | 442−15.7%314% | 524+42.3%223% | 368+6.4%209% | 346—135% | — | — | — | |
| Operating income | −46—−713% | −150—−508% | −323r−282—−690% | −301—−214% | −289—−123% | −192—−109% | −89—−34.8% | −87—−40.7% | −117r−123—−89.5% | −50r−54—−27.3% | |
| Interest expense and finance costs | 8.8+6.2%136% | 8.2+1.9%27.8% | 8.1r16+462%17.3% | 1.4+34.0%1.0% | 1.1−55.2%0.5% | 2.4−16.5%1.4% | 2.9−73.8%1.1% | 11+13.2%5.2% | 9.7−9.5%7.4% | 11—5.9% | |
| Share of profit of associates | — | — | 2.6+67.7%5.6% | 1.6+56.2%1.1% | 1.0—0.4% | −0.2—−0.1% | 0—0.0% | — | — | — | |
| Other non-operating income (expense) | 2.9−44.4%45.7% | 5.3−30.3%17.9% | 7.6r10−0.0%16.2% | 7.6—5.4% | −1.1−119%−0.5% | 5.6−64.3%3.1% | 16—6.1% | — | — | — | |
| Income before tax | −58—−905% | −153—−518% | −323r−287—−691% | −295—−210% | −291—−124% | −189r−189—−107% | −77—−29.9% | −86—−40.4% | −121r−126—−92.0% | −58r−62—−31.7% | |
| Income tax | −0.1—−1.4% | −0.3—−0.9% | −0.3r0.0−170%−0.5% | 0.4+3.2%0.3% | 0.3−3.6%0.1% | 0.4+9.8%0.2% | 0.3+7.9%0.1% | 0.3−5.3%0.1% | 0.3—0.2% | −0.1—−0.0% | |
| Income from discontinued operations | 242+129%3752% | 106+172%356% | 39—82.8% | — | — | — | — | — | — | — | |
| Net income including minority interests | 183—2849% | −48—−161% | −284—−607% | −294—−209% | −290—−123% | −189—−107% | −77—−30.0% | −86—−40.6% | −121—−92.3% | −58—−31.7% | |
| Net income attributable to shareholders | 183—2849% | −48—−161% | −284—−607% | −294—−209% | −290—−123% | −189—−107% | −77—−30.0% | −86—−40.6% | −121r−126—−92.3% | −58r−62—−31.7% | |
| Earnings per share, basic | 45.37—— | -11.89r-0.48—— | -2.92—— | -3.14—— | -3.14—— | -2.11—— | -0.89—— | -1.03—— | -1.66r-1.73—— | -0.93r-0.98—— | |
| Earnings per share, diluted | 45.37—— | -11.89r-0.48—— | -2.92—— | -3.14—— | -3.14—— | -2.11—— | -0.89—— | -1.03—— | -1.66r-1.73—— | -0.93r-0.98—— | |
| Shares, weighted average (basic) | 4.0+1.0%— | 4.0r100−95.9%— | 97+4.0%— | 94+1.3%— | 92+2.8%— | 90—— | — | — | — | — | |
| Shares, weighted average (diluted) | 4.0+1.0%— | 4.0r100−95.9%— | 97+4.0%— | 94+1.3%— | 92+2.8%— | 90+3.7%— | 87+3.1%— | 84+15.2%— | 73+16.3%— | 63—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 48−5.2%40.0% | 50−38.1%23.5% | 82r114−47.6%19.3% | 156−9.1%25.5% | 171−74.8%22.1% | 678+437%82.0% | 126+41.5%14.7% | 89−86.8%10.1% | 674+288%75.0% | 174—37.0% | |
| Short-term investments | 41—34.4% | 0−100%0.0% | 122−54.2%28.8% | 266+13.8%43.7% | 234+2773%30.2% | 8.1−98.0%1.0% | 407−23.4%47.5% | 532+757%60.4% | 62−21.8%6.9% | 79—16.9% | |
| Receivables | 0.2−55.1%0.2% | 0.5−90.6%0.2% | 5.1r13−68.6%1.2% | 16−6.3%2.7% | 17−58.5%2.2% | 42+47.2%5.1% | 28−55.3%3.3% | 64+653%7.2% | 8.5−19.1%0.9% | 10—2.2% | |
| Inventory | 3.7+18.6%3.1% | 3.2−81.6%1.5% | 17r42−57.5%4.1% | 40+30.4%6.6% | 31+87.6%4.0% | 17+140%2.0% | 6.9—0.8% | 0—0.0% | — | — | |
| Other current assets | 1.1−1.6%0.9% | 1.1−83.0%0.5% | 6.7r6.7+53.5%1.6% | 4.4r4.4−14.1%0.7% | 5.1r5.1+181%0.7% | 1.8+5.2%0.2% | 1.7−22.8%0.2% | 2.2r4.9−53.7%0.3% | 4.8+66.1%0.5% | 2.9—0.6% | |
| Current assets | 99−49.6%82.8% | 197−40.7%91.6% | 332−32.7%78.3% | 493+4.0%80.8% | 474−37.2%61.3% | 755+7.5%91.3% | 702+1.8%81.9% | 690−7.9%78.4% | 749+181%83.3% | 267—56.8% | |
| Property, plant and equipment | — | 0−100%0.0% | 4.8r13−76.8%1.1% | 21−27.1%3.4% | 28−16.0%3.7% | 34−21.3%4.1% | 43−66.4%5.0% | 127−1.8%14.4% | 129+4.7%14.4% | 124—26.3% | |
| Right-of-use (leased) assets | — | 0−100%0.0% | 65r68−18.7%15.3% | 80−12.3%13.1% | 91+4360%11.8% | 2.0+5.8%0.2% | 1.9—0.2% | 0—0.0% | — | — | |
| Investments in associates | — | — | 5.3+4.5%1.2% | 5.1+32.3%0.8% | 3.8+40.2%0.5% | 2.7—0.3% | — | — | — | — | |
| Long-term investments | 20—16.9% | 0—0.0% | — | — | — | 0.2−99.6%0.0% | 61+9.5%7.1% | 56+431%6.3% | 11—1.2% | — | |
| Total assets | 120−44.3%100% | 215−49.3%100% | 424−30.6%100% | 610−21.2%100% | 774−6.4%100% | 827−3.6%100% | 857−2.6%100% | 881−2.0%100% | 899+91.4%100% | 470—100% | |
| Accounts payable | 3.7−26.0%3.1% | 5.1−67.9%2.4% | 16r18−48.7%3.7% | 31+17.9%5.0% | 26+5.3%3.4% | 25+307%3.0% | 6.1−33.4%0.7% | 9.1+65.9%1.0% | 5.5−11.5%0.6% | 6.2—1.3% | |
| Current liabilities | 29−78.1%24.5% | 133−38.8%62.1% | 218−20.4%51.4% | 274+21.3%44.8% | 225+38.2%29.1% | 163+58.8%19.7% | 103+15.4%12.0% | 89+3.6%10.1% | 86r77+32.0%9.6% | 65—13.9% | |
| Lease liabilities (non-current) | — | 0−100%0.0% | 65r67−18.3%15.4% | 80−10.3%13.0% | 89+10308%11.5% | 0.9−9.4%0.1% | 0.9—0.1% | 0—0.0% | — | — | |
| Total liabilities | 115−71.1%96.3% | 398−32.0%186% | 586−4.2%138% | 612+12.3%100% | 545+41.3%70.4% | 385+19.7%46.6% | 322−8.6%37.6% | 352+0.3%40.0% | 351r316+19.2%39.0% | 294—62.7% | |
| Retained earnings | −1,706—−1427% | −1,889—−881% | −1,842—−435% | −1,558—−255% | −1,264—−163% | −974—−118% | −785—−91.5% | −716—−81.3% | −631r−596—−70.2% | −510r−470—−109% | |
| Shareholders' equity | −30—−25.1% | −226—−105% | −204—−48.2% | −21−110%−3.5% | 209−50.5%27.0% | 422−18.2%51.1% | 516+1.4%60.2% | 509−3.6%57.8% | 528r563+239%58.8% | 156—33.2% | |
| Minority interests | — | — | — | 200.0%3.3% | 20+3.6%2.6% | 190.0%2.3% | 190.0%2.2% | 190.0%2.2% | 190.0%2.1% | 19—4.1% | |
| Total equity | −17—−14.2% | −205—−95.6% | −184—−43.4% | −1.5−101%−0.2% | 229−48.1%29.6% | 441−17.5%53.4% | 535+1.3%62.4% | 528−3.5%60.0% | 548r582+306%61.0% | 135r175—28.8% | |
| Total liabilities and equity | 120−44.3%100% | 215−49.3%100% | 424−30.6%100% | 610−21.2%100% | 774−6.4%100% | 827−3.6%100% | 857−2.6%100% | 881−2.0%100% | 899+91.4%100% | 470—100% | |
| Shares outstanding | 4.0+0.2%— | 4.0r101−95.9%— | 99+4.9%— | 94+1.4%— | 93+1.6%— | 91+4.3%— | 88+2.6%— | 85+3.6%— | 82+29.6%— | 64—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 6.6−73.9%102% | 25−50.3%85.1% | 51−22.6%108% | 66−7.8%46.6% | 71−2.1%30.2% | 73+9.7%41.2% | 66+27.1%25.8% | 52+38.9%24.5% | 38+16.8%28.7% | 32—17.5% | |
| Cash from operating activities | −4.8—−74.1% | −138—−466% | −315—−673% | −146—−104% | −82−201%−34.9% | 82—46.3% | −79—−30.7% | −76—−35.8% | −67−1036%−50.8% | 7.1—3.9% | |
| Capital expenditure | −0.0—−0.6% | −0.3—−0.9% | −2.5—−5.4% | −3.7—−2.7% | −5.2—−2.2% | −4.0—−2.3% | −5.8—−2.2% | −8.0—−3.8% | −8.5—−6.5% | −1.3—−0.7% | |
| Cash from investing activities | 35−71.9%550% | 126−18.0%425% | 154+72.4%328% | 89—63.3% | −427−194%−181% | 452+277%257% | 120—46.8% | −522−847%−245% | 70+955%53.3% | 6.6—3.6% | |
| Shares issued | 0−100%0.0% | 0.1−96.3%0.5% | 3.7−10.8%8.0% | 4.2−67.1%3.0% | 13−66.4%5.4% | 38+82.1%21.5% | 21−30.4%8.1% | 30−14.5%14.0% | 35+253%26.6% | 9.9—5.4% | |
| Cash from financing activities | −86—−1336% | −0.3−100%−0.9% | 123+162%262% | 47—33.2% | −0.6−104%−0.2% | 13—7.6% | −4.3−131%−1.7% | 14−97.2%6.5% | 496+7268%379% | 6.7—3.7% | |
| Change in cash | −54—−843% | −12—−38.9% | −42—−89.8% | −16—−11.0% | −507−192%−216% | 552+1392%313% | 37—14.4% | −584−217%−274% | 500+2343%382% | 20—11.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4.6−37.1%100% | −1.5−209%— | 3.7+36.5%100% | 1.3*−59.3%100% | 1.1+775%100% | 1.3+35.1%100% | 2.7−89.2%100% | 3.1*—100% | 0.1r46−99.7%100% | 1.0r51—100% | 25r56—100% | — | 40—100% | |
| Cost of revenue | 4.3—93.7% | 0.0−97.6%— | 4.1+1529%110% | 0.3*—21.8% | −0.1—−5.4% | 0.1−39.3%6.3% | 0.3−98.8%9.2% | — | −0.1r5.3−102%−61.0% | 0.1r5.2—14.0% | 21r26—84.1% | — | 4.2—10.6% | |
| Research and development | 23−45.4%495% | 6.8+16.3%— | 7.6−17.5%202% | 7.3*+5.8%569% | 1.2−93.9%112% | 5.9−81.9%435% | 9.2−74.9%335% | 6.9r1.5*−80.6%219% | 20r22−67.4%16239% | 32r34—3242% | 36r38—144% | 35r52*—— | 61—152% | |
| Selling, general and administrative | 28−15.8%599% | 9.3+31.3%— | 5.9−27.7%157% | 7.3*−13.1%568% | 5.3−43.4%492% | 7.1−52.7%524% | 8.1−51.5%296% | 8.3*—266% | 9.4r18−63.4%7611% | 15r22—1494% | 17r23—65.9% | — | 26—63.7% | |
| Total costs and expenses | 55−38.4%1190% | 16+20.1%— | 18−0.6%470% | 15*+44.0%1158% | 6.5−86.4%603% | 13−71.7%994% | 18−76.3%645% | 10*−51.8%328% | 48r63−53.9%38874% | 47r62—4750% | 75r87—294% | 21r81*—— | 104—258% | |
| Operating income | −50—−1090% | −18—— | −14—−370% | −14*—−1058% | −5.4—−503% | −12—−894% | −15—−545% | −7.1r−92*—−228% | −48r−17—−38774% | −46r−11—−4650% | −49r−31—−194% | −95r−54*—— | −63—−158% | |
| Interest expense and finance costs | 9.3+8.6%201% | 2.4+17.9%— | 2.4+7.5%64.9% | 2.4*+8.8%189% | 2.1+0.7%194% | 2.0+7.5%149% | 2.3+7.9%82.4% | 2.2*−23.5%70.7% | 2.1r5.0−58.8%1682% | 1.9r4.8—187% | 2.1r5.0—8.2% | 2.9*—— | 5.0—12.5% | |
| Share of profit of associates | — | — | — | — | — | — | — | — | 0.9+32.6%730% | 1.2—118% | 0.6—2.3% | 0.6*—— | 0.7—1.7% | |
| Other non-operating income (expense) | 4.3+51.6%93.9% | 1.0+241%— | 1.1+169%29.8% | 1.3*+91.1%103% | 0.9−36.8%86.5% | 0.3−68.2%21.2% | 0.4−81.5%15.1% | 0.7r0.2*—21.9% | 1.5r3.8−65.7%1197% | 0.9r−1.3—90.2% | 2.2r2.6—8.8% | −0.4r2.5*—— | 4.3—10.7% | |
| Income before tax | −31—−670% | 12—— | −15—−405% | −15*—−1144% | −13—−1222% | −14—−1022% | −17—−612% | −8.7r−85*—−276% | −48r−18—−39259% | −47r−17—−4747% | −49r−33—−193% | −93r−57*—— | −64—−160% | |
| Income tax | −0.0—−0.0% | −0.0—— | 0−100%0.0% | 0*−100%0.0% | 0−100%0.0% | −0.1—−6.8% | 0.0−71.4%0.1% | 0.0r−0.1*—0.1% | 0.0r0.0−96.4%2.4% | −0.3r−0.3—−28.2% | 0.0r0.0—0.0% | −0.2r0.1*—— | 0.1—0.2% | |
| Income from discontinued operations | 214+151%4637% | 0−100%— | −0.1−100%−1.8% | 0.4*−98.5%30.5% | 214+585%19868% | 6.1−80.7%451% | 21+32.8%781% | 27*—850% | 31—25372% | 32—3161% | 16—63.5% | — | — | |
| Net income including minority interests | 183—3968% | 12*—— | −15−428%−407% | −14*−179%−1114% | 201*—18646% | −7.6*—−564% | 4.6—169% | 18*—574% | −17*—−13889% | −16*—−1558% | −33—−130% | −56*—— | −64*—−159% | |
| Net income attributable to shareholders | 183—3968% | 12—— | −15−428%−407% | −14*−179%−1114% | 201—18646% | −7.6—−564% | 4.6—169% | 18*—574% | −17—−13889% | −16—−1558% | −33—−130% | −56*—— | −64—−159% | |
| Earnings per share, basic | — | 2.96—— | -3.76−427%— | — | 49.61—— | -1.88—— | 1.15r0.05—— | — | -4.25r-0.17—— | -3.89r-0.16—— | -0.33—— | — | -0.65—— | |
| Earnings per share, diluted | — | 2.96—— | -3.76−427%— | — | 49.61—— | -1.88—— | 1.15r0.05—— | — | -4.25r-0.17—— | -3.89r-0.16—— | -0.33—— | — | -0.65—— | |
| Shares, weighted average (basic) | 4.0+0.1%— | 4.0+0.1%— | 4.0+0.2%— | — | 4.0+0.6%— | 4.0+1.2%— | 4.0r101−95.9%— | — | 4.0r101−95.9%— | 4.0r100—— | 99—— | — | 98—— | |
| Shares, weighted average (diluted) | 4.0+0.1%— | 4.0+0.1%— | 4.0+0.2%— | — | 4.0+0.6%— | 4.0+1.2%— | 4.0r101−95.9%— | — | 4.0r101−95.9%— | 4.0r100—— | 99—— | — | 98—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 51—50.1% | 51+117%50.1% | 37+10.1%33.7% | 48−5.2%40.0% | 118−9.9%86.1% | 23−83.4%13.1% | 34−68.2%20.3% | 50−38.1%23.5% | 131+8.3%49.5% | 141—48.0% | 106—28.9% | 82r114—19.3% | 121—26.3% | |
| Short-term investments | 41—40.2% | 41—40.2% | 50—45.8% | 41—34.4% | — | — | — | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 72—19.6% | 122—28.8% | 130—28.3% | |
| Receivables | 0.3—0.3% | 0.3+155%0.3% | 5.0+3329%4.6% | 0.2−55.1%0.2% | 0.1−99.6%0.1% | 0.1−97.9%0.1% | 0.1−99.6%0.1% | 0.5−90.6%0.2% | 29−8.4%11.0% | 6.4—2.2% | 37—10.1% | 5.1r13—1.2% | 32—6.9% | |
| Inventory | 3.4—3.3% | 3.4−12.4%3.3% | 3.4+7.3%3.1% | 3.7+18.6%3.1% | 3.9−83.9%2.8% | 3.9−84.8%2.2% | 3.2−88.5%1.9% | 3.2−81.6%1.5% | 24−41.2%9.1% | 25—8.7% | 27—7.5% | 17r42—4.1% | 41—8.8% | |
| Other current assets | 0.8—0.8% | 0.8−34.7%0.8% | 0.6−55.8%0.5% | 1.1−1.6%0.9% | 0.7−78.2%0.5% | 1.3−64.5%0.7% | 1.3−32.8%0.8% | 1.1−83.0%0.5% | 3.2−92.1%1.2% | 3.6—1.2% | 1.9—0.5% | 6.7r6.7—1.6% | 40—8.8% | |
| Current assets | 97—95.8% | 97−40.4%95.8% | 101−31.8%92.5% | 99−49.6%82.8% | 133−45.4%97.4% | 162−22.5%91.2% | 149−46.6%89.9% | 197−40.7%91.6% | 245−32.8%92.5% | 209—71.4% | 278—76.0% | 332—78.3% | 364—79.1% | |
| Property, plant and equipment | — | — | — | — | — | — | — | 0−100%0.0% | 7.6−47.6%2.9% | 11—3.7% | 12—3.3% | 4.8r13—1.1% | 15—3.2% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | 0−100%0.0% | 2.1−97.1%0.8% | 61—20.9% | 65—17.7% | 65r68—15.3% | 71—15.5% | |
| Investments in associates | — | — | — | — | — | — | — | — | 5.8+28.1%2.2% | 6.9—2.4% | 5.8—1.6% | 5.3—1.2% | 4.5—1.0% | |
| Long-term investments | 4.0—4.0% | 4.0—4.0% | 8.0—7.3% | 20—16.9% | 3.0—2.2% | — | — | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | |
| Total assets | 101—100% | 101−43.2%100% | 110−33.6%100% | 120−44.3%100% | 137−48.2%100% | 178−39.3%100% | 165−54.8%100% | 215−49.3%100% | 264−42.6%100% | 293—100% | 366—100% | 424—100% | 460—100% | |
| Accounts payable | 7.5—7.4% | 7.5−28.3%7.4% | 5.1−30.0%4.6% | 3.7−26.0%3.1% | 5.1−44.9%3.7% | 10+5.4%5.9% | 7.3+67.3%4.4% | 5.1−67.9%2.4% | 9.2−51.9%3.5% | 9.9—3.4% | 4.4—1.2% | 16r18—3.7% | 19—4.2% | |
| Current liabilities | 36—35.7% | 36−76.9%35.7% | 28−61.7%25.6% | 29−78.1%24.5% | 36−81.1%26.3% | 156+4.9%87.6% | 73−62.7%44.4% | 133−38.8%62.1% | 191−9.0%72.1% | 149—50.7% | 197—53.8% | 218—51.4% | 209—45.5% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | 0−100%0.0% | 0.7−99.0%0.3% | 58—19.9% | 63—17.1% | 65r67—15.4% | 70—15.2% | |
| Total liabilities | 109—108% | 109−69.6%108% | 119−65.0%108% | 115−71.1%96.3% | 120−74.4%87.2% | 359−25.7%202% | 340−38.4%206% | 398−32.0%186% | 466−19.0%176% | 484—165% | 552—151% | 586—138% | 576—125% | |
| Retained earnings | −1,709—−1691% | −1,709—−1691% | −1,721—−1570% | −1,706—−1427% | −1,692—−1235% | −1,892—−1063% | −1,885—−1141% | −1,889—−881% | −1,907—−721% | −1,890—−645% | −1,875—−512% | −1,842—−435% | −1,786—−388% | |
| Shareholders' equity | −30—−29.8% | −30—−29.8% | −44—−40.0% | −30—−25.1% | −17—−12.4% | −223—−125% | −217—−131% | −226—−105% | −244—−92.2% | −232—−79.2% | −228—−62.4% | −204—−48.2% | −157—−34.1% | |
| Total equity | −30—−29.3% | −30—−29.3% | −31—−28.1% | −17—−14.2% | −4.0—−2.9% | −203—−114% | −196—−119% | −205—−95.6% | −223—−84.4% | −212—−72.3% | −208—−56.8% | −184—−43.4% | −137—−29.7% | |
| Total liabilities and equity | 101—100% | 101−43.2%100% | 110−33.6%100% | 120−44.3%100% | 137−48.2%100% | 178−39.3%100% | 165−54.8%100% | 215−49.3%100% | 264−42.6%100% | 293—100% | 366—100% | 424—100% | 460—100% | |
| Shares outstanding | 4.0—— | 4.0+0.1%— | 4.0−96.0%— | 4.0+0.2%— | 4.0−96.0%— | 4.0−96.0%— | 101+1.6%— | 4.0r101−95.9%— | 101+2.5%— | 100—— | 99—— | 99—— | 98—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 4.0−68.3%86.3% | 1.0*−47.5%— | 1.2−59.6%30.8% | 1.2*+568%93.1% | 0.7*−91.4%61.5% | 1.9*−78.2%139% | 2.9−67.5%104% | 0.2*−98.1%5.7% | 7.7*−18.9%6250% | 8.6*—861% | 8.8—34.5% | 9.3*—— | 9.5*—23.6% | |
| Cash from operating activities | −38—−824% | −4.0*−131%— | −14−611%−372% | −18*—−1435% | −1.8*—−172% | 13*—941% | 2.7—99.3% | −30*—−972% | −8.4*—−6810% | −40*—−3995% | −59—−234% | −18*—— | −85*—−211% | |
| Capital expenditure | −0.0—−0.2% | 0*—— | 0—0.0% | 0*—0.0% | −0.0*—−0.8% | −0.0*—−1.0% | −0.0—−0.6% | −0.1*—−4.5% | −0.1*—−66.7% | −0.0*—−1.4% | −0.0—−0.1% | −0.3*—— | −0.7*—−1.7% | |
| Cash from investing activities | 56+2192%1216% | 18*—— | 3.0—80.7% | −52*−3101%−4049% | 87*+11444%8100% | −0.0*−100%−1.0% | −0.0−100%−0.6% | 1.7*−83.2%55.0% | 0.8*−98.6%614% | 72*—7238% | 51—202% | 10*—— | 54*—135% | |
| Shares issued | — | — | — | 0*−100%0.0% | 0*—0.0% | — | — | 0.0*−48.9%0.7% | 0*—0.0% | 0.1*—11.6% | 0—0.0% | 0.0*—— | 0*—0.0% | |
| Cash from financing activities | −86—−1861% | −0.0*—— | −0.0—−0.2% | −0.0*−380%−1.1% | −86*—−7985% | −0.0*−128%−0.7% | −0.1—−3.2% | 0.0*—0.2% | −0.1*—−103% | 0.0*—3.2% | −0.2—−0.7% | −0.2*—— | −0.0*—−0.1% | |
| Change in cash | −69—−1499% | 14*+0.0%— | −11−370%−291% | −70*—−5490% | −1.9*—−173% | 14*−61.0%1012% | 4.0—147% | −29*—−919% | −9.7*—−7895% | 35*—3505% | −8.0—−31.4% | −7.2*—— | −32*—−78.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Kyntra Bio, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Drug Product Revenue, Net$6 M91%-79%
- Development and Other Revenue$1 M9.2%-70%
Countries and regions
- Europe$6 M88%-10%
- 🇯🇵 Japan$1 M12%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Kyntra Bio, Inc. operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇰🇾 Cayman Islands | 2 subsidiaries | — |
| 🇫🇮 Finland | 1 subsidiary | — |
| 🇯🇵 Japan | $1 M12% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Kyntra Bio, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Thane Wettig | $2.1 M | $1.5 M | $1.1 M | $2 |
| 2024Thane Wettig | $2.6 M | $1.5 M | $1.0 M | $3 |
| 2023Enrique Conterno, Thane Wettig | $7.4 M | −$4.8 M | $3.1 M | $6 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Kyntra Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 7 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Delisting noticeResults announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 6, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2014 | $20 M | No. 1 | $10 to $50 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Kyntra Bio, Inc.#
3 labor condition applications certified in fiscal 2025 for 3 positions, at a median wage of $120 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, Cell Line DevelopmentBiochemists and Biophysicists | 1 | $111 K |
| SAP Technical AnalystDatabase Architects | 1 | $120 K |
| Sr. Manager, ITComputer Systems Analysts | 1 | $168 K |
Where: Atlanta, GA 1 · San Francisco, CA 1 · Plano, TX 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 3 | 3 | $120 K | 3 |
| FY2024 | 10 | 10 | $134 K | 10 |
| FY2023 | 8 | 8 | $144 K | 9 |
| FY2022 | 5 | 5 | $131 K | 5 |
| FY2021 | 12 | 12 | $141 K | 12 |
| FY2020 | 7 | 7 | $160 K | 7 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as FibroGen, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | 127 | · | · | · | · | 127 |
| 2023 | · | · | · | · | · | · | 104 | · | · | · | · | · | 104 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| effective | 127 people | LayoffWARN notice | San Francisco, California | Notice list |
| effective | 104 people | LayoffWARN notice | San Francisco, California | Notice list |
| 104 people | Restructuring planSEC 8-K | “The Plan includes an expected reduction to the Company’s U.S. workforce of approximately 32% (or 104 employees).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Kyntra Bio, Inc. compares in Biotechnology
- Revenue$6 M · higher than 37% of 647
- Revenue growth-78.3% · higher than 7% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kyntra Bio, Inc.🇺🇸 | $79 M | — | — | -78.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kyntra Bio, Inc.? Verify and update this profile — free
Show Kyntra Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.